Clinical Effect of Ilaprazole Enteric-Coated Tablets in Patients with Peptic Ulcer

Objective: To discuss the actual effect of ilaprazole enteric-coated tablets in the treatment of peptic ulcer patients. Methods: 200 peptic ulcer patients who received treatment from January to December 2023 were selected as the study sample, and all patients were randomly and evenly divided into the study group (n = 100) and the control group (n = 100), and the serum inflammatory factors and the disappearance time of symptoms were compared. Results: After treatment, the serum inflammatory factors in the observation group were better than those in the control group, and the time of belching and burning sensation in the observation group was shorter than that in the control group, all of which were statistically significant (P Conclusion: Ilaprazole enteric-coated tablets in the treatment of peptic ulcer have a good effect and can effectively improve the symptoms of patients with clinical signs, with reference significance.

Analysis of the Therapeutic Effect of Clopidogrel Bisulfate Tablets + Aspirin Enteric-Coated Tablets on Acute Myocardial Infarction

Objective:To investigate and analyze the clinical effect of clopidogrel bisulfate tablets combined with aspirin enteric-coated tablets on acute myocardial infarction(AMI)patients.Methods:The study period was from January 2020 to December 2023,the sample source was 82 AMI patients admitted to our hospital,grouped into an observation group(n=41)and a control group(n=41)by the numerical table method.The patients in the control group were treated with aspirin enteric-coated tablets,and the patients in the observation group were treated with aspirin enteric-coated tablets combined with clopidogrel bisulfate.The clinical efficacy,coagulation indexes,and the incidence of cardiovascular adverse events between the two groups were compared.Results:The clinical efficacy of the observation group was higher than that of the control group(P<0.05);the platelet aggregation rate(PAR)of the observation group was lower than that of the con-trol group after treatment(P<0.05),and there was no significant difference in the prothrombin time(PT)and activated partial thromboplastin time(APTT)between the two groups(P>0.05).The incidence of cardiovascular adverse events in the observation group was lower than that of the control group(P<0.05).Conclusion:The treatment effect of clopidogrel bisulfate tablets combined with aspirin enteric-coated tablets on AMI patients is remarkable.It reduces the PAR and the incidence of cardiovascular adverse events,so this treatment method should be popularized.

Formulation Development of Generic Omeprazole 20 mg Enteric Coated Tablets

Omeprazole is a potent proton pump inhibitor with powerful inhibition of secretion of gastric juice. Oral site-specific drug delivery systems have recently attracted a great interest for the local treatment of bowel disease and for improving systemic absorption of drugs which are unstable in the stomach. However, microenvironment in the gastrointestinal tract and varying absorption mechanisms cause hindrance for the formulation and optimization of oral drug delivery. The objective of the study was to develop and optimize enteric coating process for omeprazole tablets. Different batches of core tablets were sub coated, one set sub coated with opadry and another with a mixture of light magnesium oxide, magnesium stearate and absolute alcohol omeprazole magnesium. Seal coating was applied by using opadry to achieve certain weight gain and to protect omeprazole from acidic coating polymers. A comparative dissolution test was performed. The variation of thickness and diameter were observed to be minimal with a weight gain of 3% - 4% of enteric polymer. Disintegration test showed that in each tested batch the enteric coated layer remained intact in 0.1N HCl for 2 hours and when exposed to alkaline media of phosphate buffer pH 6.8, it dissolved within few minutes. Dissolution release was 98.8% to 102.4% within two hours when the product was exposed to phosphate buffer pH 6.8 after 2 hours. The similarity and dis-similarity factors were calculated and observed to be 54 to 61 and 4 to 5 respectively. Therefore a simple and good enteric coating process was developed and tested with potential for transfer this technology into local pharmaceutical industries using cheap and easily available materials.

疏肝和胃方联合奥美拉唑治疗门诊胃痞病肝胃不和证的效果观察

目的:研究疏肝和胃方联合奥美拉唑治疗门诊胃痞病肝胃不和证的效果。方法:选取2022年1—12月苏州市相城人民医院门诊收治的206例胃痞病肝胃不和证患者。根据随机数表法将其分为对照组和观察组,各103例。两组均给予常规治疗。对照组采用奥美拉唑治疗,观察组采用疏肝和胃方联合奥美拉唑治疗。比较两组治疗3个月后临床效果,治疗前、治疗3个月后肠胃功能指标、应激指标及不良反应。结果:观察组总有效率为92.23%,高于对照组的77.67%,差异有统计学意义(P<0.05)。治疗3个月后,观察组胃动素(MTL)、胃蛋白酶原Ⅱ(PGⅡ)水平均高于对照组,差异有统计学意义(P<0.05)。治疗3个月后,观察组P物质(SP)水平高于对照组,热休克蛋白(HSP)水平低于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:疏肝和胃方联合奥美拉唑治疗门诊胃痞病肝胃不和证效果显著,有利于改善患者的肠胃功能与应激指标,且安全。

Gradient high performance liquid chromatography method for simultaneous determination of ilaprazole and its related impurities in commercial tablets

A methodology(HPLC)proposed in this paper for simultaneously quantitative determination of ilaprazole and its related impurities in commercial tablets was developed and validated.The chromatographic separation was carried out by gradient elution using an Agilent C8 column(4.6 mm×250 mm,5 mm)which was maintained at 25℃.The mobile phase composed of solvent A(methanol)and solvent B(solution consisting 0.02 mmol/l monopotassium phosphate and 0.025 mmol/l sodium hydroxide)was at a flow rate of 1.0 ml/min.The samples were detected and quantified at 237 nm using an ultraviolet absorbance detector.Calibration curves of all analytes from 0.5 to 3.5 mg/ml were good linearity(r≥0.9990)and recovery was greater than 99.5% for each analyte.The lower limit of detection(LLOD)and quantification(LOQ)of this analytical method were 10 ng/ml and 25 ng/ml for all impurities,respectively.The stress studies indicated that the degradation products could not interfere with the detection of ilaprazole and its related impurities and the assay can thus be considered stability-indicating.The method precisions were in the range of 0.41-1.21 while the instrument precisions were in the range of 0.38-0.95 in terms of peak area RSD% for all impurities,respectively.This method is considered stabilityindicating and is applicable for accurate and simultaneous measuring of the ilaprazole and its related impurities in commercial enteric-coated tablets.

Delayed-release oral mesalamine tablet mimicking a small jejunal gastrointestinal stromal tumor:A case report

BACKGROUND Enteric-coated medications are supposed to pass intact through the gastric environment and to release the drug content into the small intestine or the colon.Before dissolution of the enteric coating,they may appear hyperdense on computed tomography(CT).Unfortunately,few reports have been published on this topic so far.In this case report,the hyperdense appearance on contrastenhanced CT of an enteric-coated mesalamine tablet was initially misinterpreted as a jejunal gastrointestinal stromal tumor(GIST).CASE SUMMARY An asymptomatic 81-year-old male patient,who had undergone laparoscopic right nephrectomy four years earlier for stage 1 renal carcinoma,was diagnosed with a jejunal GIST at the 4-year follow-up thoraco-abdominal CT scan.He was referred to our hub hospital for gastroenterological evaluation,and subsequently underwent 18-fluorodeoxyglucose positron emission tomography,abdominal magnetic resonance imaging,and video capsule endoscopy.None of these examinations detected any lesion of the small intestine.After reviewing all the CT images in a multidisciplinary setting,the panel estimated that the hyperdense jejunal image was consistent with a tablet rather than a GIST.The tablet was an 800 mg delayed-release enteric-coated oral mesalamine tablet(Asacol®),which had been prescribed for non-specific colitis,while not informing the hospital physicians.CONCLUSION Delayed-release oral mesalamine(Asacol®),like other enteric-coated medications,can appear as a hyperdense image on a CT scan,mimicking a small intestinal GIST.Therefore,adetailed knowledge of the patients’medications and a multidisciplinary review of the images areessential.

旋覆代赭汤加味治疗胃食管反流性咳嗽临床研究

目的:观察旋覆代赭汤加味治疗胃气上逆型胃食管反流性咳嗽(gastroesophageal reflux cough,GERC)的临床疗效。方法:将82例胃气上逆型GERC患者按照随机数字表法分为对照组和研究组,每组各41例。对照组给予奥美拉唑镁肠溶片及枸橼酸莫沙必利片治疗,研究组在对照组治疗的基础上给予旋覆代赭汤加味治疗。比较两组患者的临床疗效及治疗前后中医证候积分、食管运动指标(食管上括约肌静息压、湿咽成功率、食管下括约肌静息压)、胃肠激素水平[血管活性肠肽(vasoactive intestinal peptide,VIP)、胃动素(motilin,MTL)、胃泌素(gastrin,GAS)]、生活质量评分变化情况。结果:研究组有效率为90.24%,对照组有效率为73.17%,两组患者有效率比较,差异具有统计学意义(P<0.05)。两组患者治疗后中医证候积分低于本组治疗前,且治疗后研究组低于对照组,差异具有统计学意义(P<0.05)。两组患者治疗后日间、夜间咳嗽症状积分低于本组治疗前,且治疗后研究组低于对照组,差异具有统计学意义(P<0.05)。两组患者治疗后食管上括约肌静息压、湿咽成功率、食管下括约肌静息压高于本组治疗前,且治疗后研究组高于对照组,差异具有统计学意义(P<0.05)。两组患者治疗后VIP低于本组治疗前,MTL、GAS高于本组治疗前,且治疗后组间比较,差异具有统计学意义(P<0.05)。两组患者治疗后社会功能、心理健康、生理情况等生活质量评分高于本组治疗前,且治疗后研究组高于对照组,差异具有统计学意义(P<0.05)。结论:旋覆代赭汤加味治疗胃气上逆型胃食管反流性咳嗽疗效确切,可显著缓解患者的临床症状,改善食管运动指标及胃肠激素水平。

奥美拉唑碳酸氢钠干混悬剂(Ⅱ)四联疗法与雷贝拉唑钠肠溶片四联疗法治疗幽门螺旋杆菌阳性患者的效果比较

目的 对比奥美拉唑碳酸氢钠干混悬剂(Ⅱ)四联疗法与雷贝拉唑钠肠溶片四联疗法治疗幽门螺旋杆菌(Hp)阳性患者的临床效果。方法 88例Hp阳性患者随机分为两组,对照组给予雷贝拉唑钠肠溶片+阿莫西林片+克拉霉素片+枸橼酸铋钾颗粒治疗,研究组给予奥美拉唑碳酸氢钠干混悬剂(Ⅱ)+阿莫西林片+克拉霉素片+枸橼酸铋钾颗粒治疗,比较两组的Hp根除率、抑酸效应及炎性因子水平。结果 治疗后,研究组的Hp根除率高于对照组,胃内24 h平均pH值高于对照组,抑酸起效时间短于对照组,抑酸持续时间长于对照组,血清IL-6、 CRP水平均低于对照组(P<0.05)。结论 与雷贝拉唑钠肠溶片四联疗法相比,奥美拉唑碳酸氢钠干混悬剂(Ⅱ)四联疗法对Hp的根除效果更佳,可更好地发挥抑酸效应,降低患者炎性因子水平。

氟哌噻吨美利曲辛片联合奥美拉唑、莫沙必利在慢性胃炎伴反流性食管炎治疗中的应用价值分析

探讨慢性胃炎伴反流性食管炎患者应用氟哌噻吨美利曲辛片联合奥美拉唑、莫沙必利治疗的效果。选取2022年1月—2022年12月武汉体育学院校医院收治的82例慢性胃炎伴反流性食管炎患者为研究对象,采用随机数字表法将其分为对照组和观察组,每组41例。对照组联合应用奥美拉唑、莫沙必利治疗,观察组联合应用氟哌噻吨美利曲辛片、奥美拉唑、莫沙必利治疗。对比两组患者治疗效果。结果显示,观察组患者治疗总有效率高于对照组(P<0.05),胃肠激素和炎症因子水平优于对照组(P<0.05)。研究发现,慢性胃炎伴反流性食管炎患者应用氟哌噻吨美利曲辛片联合奥美拉唑、莫沙必利治疗方案的临床效果显著,可改善患者胃肠激素和炎症因子水平,安全性高,利于患者康复,值得推广应用。

基于24h食管阻抗-pH监测及血清学指标变化评估降逆益中汤治疗胃食管反流病的疗效

目的探讨降逆益中汤在胃食管反流病(GERD)患者治疗中的应用及药理作用。方法用随机数字表法将80例于2021年1月-2021年12月在河南省中医院接受治疗的胃食管反流病患者分为A、B两组,各40例。A组给予基础治疗,同时给予奥美拉唑肠溶胶囊及枸橼酸莫沙必利片,B组在A组基础上给予降逆益中汤。2组均持续治疗4周。结果治疗4周后,B组的总有效率为97.50%,A组为80.00%,B组的中医证候疗效明显优于A组(P<0.05)。2组治疗4周后的血清高敏C反应蛋白(hs-CRP)、白细胞介素6(IL-6)水平及p H值<4时间百分比均低于治疗前,且B组比A组低;血清胃蛋白酶原Ⅰ(PGⅠ)、胃泌素-17(G-17)水平均高于治疗前,且B组比A组高;弱碱反流、弱酸反流、酸反流次数均少于对照组,且B组弱碱反流次数比A组少(P<0.05)。B组及A组治疗期间的不良反应发生率比较差异没有统计学意义(P>0.05)。结论中药降逆益中汤能够减轻胃食管反流病患者机体炎症反应,有效改善患者胃肠分泌功能,进而提高临床疗效,安全性良好。

奥美拉唑镁肠溶片联合复方枸橼酸铋钾甲硝唑胶囊治疗幽门螺杆菌感染相关消化性溃疡的疗效观察

目的评价奥美拉唑镁肠溶片联合复方枸橼酸铋钾甲硝唑胶囊用于根治幽门螺杆菌(Hp)感染相关消化性溃疡(PU)的有效性及安全性。方法将2020年1月至2022年7月于厦门市同安区新民街道社区卫生服务中心收治并筛选Hp阳性的A期PU患者(98例)行随机、盲法对照临床研究,分为观察组与对照组各49例,分别采用奥美拉唑镁肠溶片联合复方枸橼酸铋钾甲硝唑胶囊治疗、奥美拉唑镁肠溶片治疗,均治疗2周。比较两组患者的胃肠激素水平、应激反应、免疫功能,同时比较两组的Hp清除率、Hp清除时间和溃疡愈合时间,以及治疗有效率、不良反应率。结果与治疗前相比,治疗2周后两组患者的血清丙二醛(MDA)、脂质过氧化物(LPO)、胃动素(MTL)、胃泌素(GAS)水平均下降,一氧化氮(NO)、降钙素基因相关肽(CGRP)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)水平均升高,且观察组患者的MDA、LPO、MTL、GAS水平均低于对照组患者,NO、CGRP、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)水平均高于对照组患者,差异有统计学意义(P<0.05)。治疗2周后,观察组患者的Hp清除率均高于对照组患者,Hp清除时间、溃疡愈合时间均短于对照组患者,差异有统计学意义(P<0.05)。观察组治疗有效率高于对照组(93.9%vs.71.4%,P=0.003),观察组与对照组不良反应率比较差异无统计学意义(12.2%vs.20.4%,P=0.274)。结论Hp感染相关PU患者应用奥美拉唑镁肠溶片联合复方枸橼酸铋钾甲硝唑胶囊治疗的有效性、安全性均较高,主要体现在可减轻患者的应激反应,改善胃肠功能,增强免疫功能以及有效根治Hp。

奥美拉唑肠溶微丸片的制备及体外释放度考察

目的制备一种奥美拉唑肠溶片剂。方法采用挤出-滚圆法制备奥美拉唑微丸,将奥美拉唑微丸与辅料压片,再对片剂分别用HPMC E50和EudragitRL30D-55包衣,制成奥美拉唑肠溶片。结果体外释放度实验显示,制备的奥美拉唑片在酸性介质中2h稳定性良好,在碱性介质中45min基本释药完全。结论用该方法制备奥美拉唑肠溶片,稳定性好,工艺简便,易于操作。

奥美拉唑镁肠溶片与奥美拉唑胶囊治疗消化性溃疡的临床随机对照研究

目的 验证奥美拉唑镁肠溶片与奥美拉唑胶囊治疗消化性溃疡的生物等效性及评价其不良反应。方法 采用随机对照和开放试验的方法治疗经胃镜检查证实的消化性溃疡共 171例 ,其中奥美拉唑镁肠溶片组 (试验组 ) 68例 ,胃溃疡 2 1例 ,十二指肠溃疡 47例 ;奥美拉唑胶囊组 (对照组 ) 67例 ,其中胃溃疡 2 1例 ,十二指肠溃疡 46例 ;开放试验组 3 6例 ,其中十二指肠溃疡 2 9例 ,胃溃疡 7例。结果 试验组中胃溃疡的愈合率和总有效率分别为 80 9%和 10 0 %十二指肠溃疡的愈合率和总有效率分别为87 2 %和 97 8% ;对照组中胃溃疡的愈合率和总有效率为 85 7%和 95 2 % ,十二指肠溃疡的愈合率和总有效率为 84 7%和 97 8% ;开放试验组中胃溃疡的愈合率和总有效率均为 10 0 0 %十二指肠溃疡的愈合率和总有效率分别为 86 2 %和 10 0 % ;试验组中疼痛消失率及其他消化道症状的消失率在胃溃疡为 95 2 %和 89 0 %在十二指肠溃疡则为 97 8%和 98 3 % ;对照组中疼痛及其他消化道症状的消失率在胃溃疡为 95 2 %和 92 7% ,在十二指肠溃疡为 97 8%和 98 7%。两组在愈合率、总有效率、疼痛消失率和其他消化道症状消失率方面相比均无显著差别 (P >O 0 5 )。两组在治疗过程中均未见明显的不良反应。

奥美拉唑镁肠溶片治疗上消化道溃疡出血的疗效及不良反应评价

目的:探讨奥美拉唑镁肠溶片治疗上消化道溃疡出血的临床疗效及不良反应。方法:回顾性分析2008年12月～2009年6月我院收治的上消化道溃疡出血患者90例的临床资料,所有患者随机分为两组各45例,对照组采用泮托拉唑钠治疗,观察组采用奥美拉唑镁肠溶片治疗。结果:观察组总有效率为95.6%,明显高于对照组的82.2%,差异有统计学意义(P<0.05)。两组均未见明显不良反应。结论:应用奥美拉唑镁肠溶片治疗上消化道溃疡出血疗效安全、可靠,值得临床推广。

疏肝和胃降逆法治疗反流性食管炎疗效观察

目的观察中西医结合方法治疗反流性食管炎的临床疗效。方法将120例符合诊断标准的门诊及住院患者随机分为两组,治疗组60例和对照组60例。对照组60例应用西药奥美拉唑胶囊治疗和黛力新(氟哌噻吨美利曲辛片),治疗组60例应用奥美拉唑胶囊与自拟方和胃合剂,对照组和治疗组均连续治疗10周为1个疗程,连续治疗3个疗程。观察两组的临床疗效和不良反应。并在治疗0.5～1年内进行随访。结果经过3个疗程的治疗后,治疗组有效率为100.00%,对照组总有效率62.67%,两组比较临床疗效差异有统计学意义(P<0.05)。治疗组0.5～1年随访复发率20.00%;对照组0.5～1年随访复发率42.77%,两组复发率比较差异有统计学意义(P<0.05)。结论奥美拉唑胶囊联合和胃合剂治疗反流性食管炎,患者症状消失或好转均较对照组治疗效果好,其疗效明显高于单独用药,且复发率低,值得临床推广。

百蕊片治疗反流性咽喉炎的临床观察

目的探讨百蕊片治疗反流性咽喉炎的疗效。方法选择2009年10月至2011年12月佛山市中医院耳鼻咽喉科门诊诊断为反流性咽喉炎患者共120例,随机分为治疗组与对照组。对照组口服奥美拉唑,治疗组口服奥美拉唑和百蕊片,疗程均为8周。在治疗后2周、4周、8周,对两组进行症状和体征评分。结果治疗2周、4周、8周两组症状与体征积分逐渐减少,与治疗前比较差异有统计学意义(P<0.05或P<0.01);治疗4周,治疗组症状、积分疗效优于对照组(P<0.05);治疗8周,治疗组症状、积分继续减少,与对照组比较差异有统计学意义(P<0.01)。结论在奥美拉唑治疗的基础上,应用百蕊片治疗反流性咽喉炎疗效明显,显著优于单用奥美拉唑。

奥美拉唑肠溶片对5-氟尿嘧啶化疗的结肠癌患者胃肠道反应的预防作用研究

目的观察奥美拉唑肠溶片对5-氟尿嘧啶(5-FU)化疗的结肠癌患者胃肠道反应的预防作用研究。方法2009年6月～2011年12月杭州市第一人民医院收治60例结肠癌患者按随机数字表法分为对照组与实验组,两组患者均经5-FU化疗,对照组在化疗的第1天即给予阿扎司琼、地塞米松;实验组在对照组治疗方案的基础上加用奥美拉唑肠溶片。比较两组对急慢性呕吐、恶心预防的总有效率及不良反应发生率。结果实验组对急性恶心、呕吐的预防有效率均为93.3%,对照组对急性恶心、呕吐的预防有效率分别为86.7%和90.0%,两组比较差异均无统计学意义(P>0.05);实验组在第2、3、4、5天对预防慢性恶心的总有效率分别为86.7%、83.3%、90.0%、93.3%,均高于同期对照组的73.3%、70.0%、73.3%、73.3%(P<0.05);实验组在第2、3、4、5天对预防对呕吐的总有效率分别为93.3%、86.7%、96.7%、100.0%,均高于同期对照组的80.0%、76.7%、83.3%、83.3%(P<0.05);实验组与对照组不良反应发生率分别为13.3%、16.7%,差异无统计学意义(P>0.05)。结论质子泵抑制剂奥美拉唑肠溶片连用止呕剂可预防经5-FU化疗结肠癌患者的急慢性呕吐、恶心等胃肠道反应。

奥美拉唑联合氟哌噻吨美利曲辛片治疗胃食管反流的效果分析

目的分析奥美拉唑联合氟哌噻吨美利曲辛片治疗胃食管反流的临床效果。方法选取100例本院收治的胃食管反流患者为研究对象,以抽签法随机分为观察组与对照组,两组均为50例,对照组采用奥美拉唑治疗,观察组采用奥美拉唑联合氟哌噻吨美利曲辛片治疗,比较两组患者在不同阶段的治疗效果以及观察组不同疗程的胃镜检查结果。结果采取联合治疗的观察组4周后总有效率为78.0%,6周后为90.0%,与对照组的62.0%(4周)、76.0%(6周)比较,差异有统计学意义(P<0.05);观察组患者0周胃镜积分等级(0级0例、1级19例、2级22例、3级9例)与4周(20级0例、1级10例、2级18例、3级2例)或6周(0级41例、1级7例、2级2例、3级0例)比较,差异有统计学意义(P<0.05)。结论奥美拉唑联合氟哌噻吨美利曲辛片治疗胃食管反流的临床效果优于单一奥美拉唑治疗,6周后胃镜检查结果显著优于4周,可见联合用药具有较高的临床应用价值,而奥美拉唑治疗疗程适宜设定为6周。

氟哌噻吨美利曲辛片联合莫沙必利治疗慢性胃炎伴反流性食管炎的疗效观察

目的探究氟哌噻吨美利曲辛片联合奥美拉唑与莫沙必利治疗慢性胃炎伴反流性食管炎的临床效果。方法230例慢性胃炎伴反流性食管炎患者,随机分为对照组(110例)和观察组(120例)。对照组采用氟哌噻吨美利曲辛片联合奥美拉唑治疗,观察组采用氟哌噻吨美利曲辛片联合莫沙必利治疗。对比两组临床疗效、用药不良反应及焦虑、抑郁情绪。结果观察组总有效率为95.83%,高于对照组的88.18%,差异有统计学意义(P<0.05)。两组用药后不良反应发生率比较,差异无统计学意义(P>0.05)。治疗前,两组焦虑自评量表(SAS)与抑郁自评量表(SDS)评分比较差异无统计学意义(P>0.05);治疗后,观察组SAS评分(32.15±2.64)分、SDS评分(33.26±3.18)分均低于对照组的(44.36±3.78)、(46.17±5.06)分,差异有统计学意义(P<0.05)。结论慢性胃炎伴反流性食管炎患者应用氟哌噻吨美利曲辛片联合莫沙必利治疗疗效显著,可有效改善患者焦虑、抑郁情绪,且安全性高,可作为首选方案。

高效液相色谱法测定奥美拉唑肠溶片的含量

:建立了采用高效液相色谱法测定奥美拉唑肠溶片含量的方法。以甲醇为溶剂 ,色谱柱 Waters Nova- Pak C1 8,流动相为磷酸盐缓冲液 (p H7.6 ) -乙腈 (75∶ 2 5 ) ,检测波长设定在 30 2 nm。线性范围为进样量 0 .10 μg～ 0 .81μg,γ=0 .9999,平均回收率为 10 0 .1% ,RSD=1.19%。本方法快速简便 ,精密度好 ,灵敏度高 ,可作为控制奥美拉唑肠溶片质量的方法。